A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
← catalyst calendarSponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
157estimated
Sites
23
Countries
Japan, South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-03 | actual | When the study began enrolling |
| Primary completion | 2024-12-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)
Interventions
- Drug: Placebo
- Drug: KK4277
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Part 1 : from Day 1 through at most Day 113, Part 2: from Day 1 through at most Day 169
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed